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ABSTRACT
Doxorubicin (Dox) has been used widely in breast cancer therapy. One of the 
problems in chemotherapy is the development of resistance to chemotherapy 
that lead to metastasis and relapse aggressiveness of cancer. MicroRNAs 
(miRNAs) are small non-coding RNA that regulate protein expression and play 
role in carcinogenesis, as well as cancer chemotherapy resistance. miR-451 is 
classified as tumour suppressor miRNA, that binds to messenger RNA (mRNA) 
of MDR1, and leads disruption of  P-glycoprotein (Pgp) expression. The study 
aimed to investigate the association between miR-451 and Pgp related with Dox 
resistance mechanism. In silico analysis was conducted to predict the binding 
affinity between miR-451 and mRNA of MDR1. The MCF-7 cell line was used as 
wild type model, while MCF-7/Dox was used as a model of resistance. qPCR was 
conducted to calculate miR-451 expression and immunocytochemistry was used 
to observe Pgp expression. miRNA was down-regulated in both on MCF-7 and 
MCF-7/Dox. On the other hand, Pgp expression was detectable in the cytoplasmic 
and cytoplasmic membrane in MCF-7/Dox. The Pgp expression was higher in 
the MCF-7/Dox compared to MCF-7. In conlusion, the over expression of Pgp is 
associated with the resistance to MCF-7/Dox.
ABSTRAK 
Doxorubisin (Dox) adalah salah satu kemoterapi yang telah digunakan secara 
klinis dalam terapi kanker payudara. Salah satu masalah dalam kemoterapi 
adalah perkembangan resistensi terhadap kemoterapi yang akan mengarah 
pada metastasis dan kekambuhan agresivitas kanker. MicroRNAs (miRNAs) 
merupakan untai RNA kecil yang dapat mengatur ekspresi protein dan berperan 
dalam karsinogenesis, serta resistensi obat kemoterapi. miR-451 diklasifikasikan 
sebagai miRNA penekan tumor, yang berikatan dengan messenger RNA (mRNA) 
MDR1 yang, dan menyebabkan gangguan ekspresi P-glycoprotein (Pgp). Tujuan 
dari penelitian ini adalah untuk memahami hubungan antara miR-451 dan Pgp 
terkait dengan mekanisme resistensi Dox. Analisis in silico dilakukan untuk 
memprediksi afinitas pengikatan antara miR-451 dan mRNA MDR1. Sel line 
MCF-7 digunakan sebagai wild-type sedangkan MCF-7/Dox, digunakan sebagai 
model resistensi. Kuantifikasi ekspresi miR-451 diukur menggunakan qPCR 
dan imunositokimia digunakan untuk mengamati ekspresi Pgp. miRNA-451 
ditemukan mengalami penurunan ekspresi baik pada sel MCF-7 dan MCF-7/Dox. 
Dalam penelitian ini, Pgp ditemukan terekspresi dalam membran sitoplasma 
dan sitoplasma sel MCF-7/Dox dan MCF-7. Ekspresi PgP ditemukan terekspresi 
lebih tinggi pada MCF-7/Dox dibandingkan dengan MCF-7 wild-type. Dapat 
disimpulkan, tingkat ekspresi Pgp ini berkaitan dengan resistensi MCF-7/Dox.
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 INTRODUCTION
Cancer is a genetic disease as 
result of the accumulation of genetic 
alterations which causeless regulation in 
the cell and the cellular environment.1,2 
The certain genotype and phenotype 
complexity in cancer furthermore can 
be utilized as tumour biomarker which 
useful for tumour diagnosis, prognosis, 
and risk prediction of relapse.3 The high 
incidence and mortality in breast cancer 
patients are caused by the difficulty 
of early diagnosis and the low level of 
successful treatment which also lead to 
high risk of the side effect of therapies.1
Doxorubicin (Dox) is one 
chemotherapy used clinically in cancer.4-7 
Resistance to chemotherapy, such as 
Dox, causes tumour progressiveness 
by forming certain adaptation to the 
environment, both in tumour genotype 
and phenotype. This condition can 
encourage massive cellular proliferation 
and escape from anticancer drug 
treatment.5,8 One of the causes of the 
resistance to chemotherapy in cancer 
is related to ATP-binding cassette 
transporter (ABC-transporter), a drug 
transporter. MDR1 gene express Pgp 
which has a function in efflux pump 
mechanism in drug resistance.9-11
MicroRNAs (miRNAs) are 18-24 
long nucleotide that play an important 
role in protein expression regulation by 
binding to the messenger RNA (mRNA) of 
genes which led to post-transcriptional 
inhibition. Several studies indicate 
expression related to miRNA in cases 
of resistance to cancer.9,11 In the 
previous study, microRNA 451 (miR-
451) has been identified as negative 
post-transcriptional regulator of MDR-
1 and Pgp so that it could lead to the 
proliferation inhibition and apoptosis in 
some breast cancer cell lines.12
Regulation of miRNA in drug 
mechanism associated with resistance 
can be used potentially as a biomarker 
for resistance.3,13 miRNA profiling 
analysis in the cancer cells is a potential 
method to know the correlation of miRN 
as to various phenotypic complexity in 
particular cancer cells. In this study, we 
investigated the mechanism of resistance 
to Dox in the cancer cells. We developed 
Dox resistance cell line in MCF-7 breast 
cancer cell line as a cell model to 
investigate the expression of miR-451 
and Pgp protein which expressed by 
MDR1 gene.
MATERIALS AND METHODS
In silico binding analysis of miR-451 to 
mRNA MDR1 (ABCB1)
In silico bioinformatics analysis 
method was used to analyze the binding. 
Sequence database was obtained 
from miRBase (http://www/.mirbase.
org), while sequence mRNA target was 
obtained from Genebank (http://www.
ncbi/genbank). Interaction analysis was 
conducted through UTRdb database 
software online (http://utrdb.ba.itb.cnr.
it/) and UTRscan (http://itbtolls.ba.itb.
cnr.it/utrscan/). RNAhybrid free online 
software (http://bibiserv.techak.uni-
bielefeld.de/rnahybrid/) was used to 
calculate the minimum free energy of 
binding sequence miRNA-mRNA.
MCF-7 cell resistance Dox (MCF/Dox) 
induction
MCF-7 cell line was obtained from 
Stem Cell and Cancer Institute, Jakarta, 
Indonesia. The cell was cultured in 
Dulbecco modified eagle medium 
(DMEM) with 10% fetal bovine serum 
(FBS) and incubated in 5% CO2 at 37°C. 
The resistance cell line was 
produced by the stepwise increased 
dose of Dox treatment to the cell every 
2 or 3 days. IC50 of MCF-7 wild-type was 
determined first as a basis concentration 
of Dox concentration which would be 
administrated to the cells. Then, 1, 2, and 
5% from IC50 Dox concentration were 
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gradually administrated, respectively.
MTT assay
Cytotoxic test was conducted by MTT 
assay method using MCF-7 wild type and 
MCF-7/Dox to determine the IC50 which 
would be used to determine the level of 
resistance of MCF-7/Dox cells compared 
to MCF-7 wild-type cells. MCF-7 line 
cells were grown on a 96-well plate and 
incubated for 24 h at 370C and 5% CO2. 
The media was removed from the well 
plate, and the prepared test solution 
were put into the well (100 μL/well) then 
incubated again for 24 h at 370C and 5% 
CO2. The test solution was removed and 
the well plate was filled with 100 μL MTT 
0.5 mg/mL. After incubation for 4 h, add 
100 μL stop solution (SDS 10%, and 0.01 
M HCl) to dissolve formazan crystals 
and incubate again for 18 h at room 
temperature in the absence of light. The 
absorbance of each was measured at a 
λ 550-600 nm wavelength using micro 
plate reader (Bio-Rad Model 680 XR).
Expression of ER, caspase 3 and Pgp.
The  expression  level of Pgp, ER 
and  caspase 3 were  determined   using 
immunohistochemistry. Immunohisto-
chemistry was conducted using primary 
antibody anti-human monoclonal anti-
bodies Dako Envision SystemTM (USA) for 
ER antibody, caspase 3 and Pgp. Second-
ary antibody, labelled with biotin (Bioti-
nylated Universal Secondary Antibody) 
Trek-Avidin HRP marker, was also used 
according to the manufacturer’s proto-
cols.
Expression of miR-451. 
Isolataion of total RNA of wildtype 
MCF-7 and MCF-7/Dox was conducted 
using miRCURYTM RNA Isolation Kit – Cell 
& Plant (Exiqon Inc, USA). The RNA was 
then subjected to cDNA synthesis using 
miRCURY LNA Universal RT microRNA 
PCR (Exiqon Inc, USA). The both 
protocols were conducted according to 
the manufacturer’s protocols.
Quantitative real-time PCR had been 
done using miRCURY SYBR Green Master 
Mix (Exiqon Inc, USA) and hsa-miR-451 
primer-specific LNA (locked nucleic 
acid) according to the manufacturer’s 
protocols. The results of the qPCR were 
then analyzed using GeneEx 6 Multi-D 
software. The relative expression was 
calculated using the Livak method by 
comparing the cycle quantification value 
(Cq) of wildtype MCF-7 or MCF-7/Dox.
RESULTS
miR-451 targets mRNA MDR1 (ABCB1). 
RNA hybrids software was used to 
investigate the interaction between miR-
145 and mRNA of MDR1. FIGURE 1 shows 
the binding position of miR-451 to the 
3’UTR coding region of MDR1’s mRNA. 
The binding locations were on base 
pair 4246 to 4266 and 4334 to 4718 with 
minimum free energy of the binding was 
-6.10 kJ/mol
FIGURE 1. miR-451-mRNA MDR1 interaction prediction through in-silico analysis.
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Dox resistance MCF7 cells
The gradual concentration of Dox 
was administrated to the MCF-7 cell 
line at given period for making the Dox 
resistance MCF-7 cells. The detail of 
Dox treatment to the cells was shown 
in TABLE 1, while the MCF-7 parental 
induction resistance proses to get MCF-7/
Dox is shown in FIFURE 2. 
TABLE 1. Resistance induction proses on MCF7 parental to get MCF7/Dox. 
Freezing process and subculture was done routinely before 
treatment.
Treatment 
description
Time (week)
1 2 3 4 5 6 7 8 9
Cell viabiliy (%) 75 25 50 75 30 45 60 75 10
Treatment 1% Rec Rec 2% Rec Rec Rec 5% X
IC50 IC50 IC50
Note: Rec = recovery; X = cell death
 
FIGURE 2. MCF-7 parental induction resistance 
process to get MCF-7/Dox
Originally, the wild-type MCF7 
was epithelial like cells, but after the 
exposure of Dox, the morphology of cell 
was changed (FIGURE 3A and B). The 
change of the morphological stucture 
of the lamellipodia in the cytoplasm 
component was observed in the Dox-
treated cells after 5 weeks of the Dox 
treatment (FIGURE 3B). The change 
was as a form of adaptation to the 
cell adhesion due to the effect of Dox 
treatment.
The resistance of MCF-7/Dox was 
proven as presented the change of the 
IC50 value after 5 weeks Dox treatment. 
The IC50 of MCF-7/Dox increased 7.5 fold 
higher (IC50: 15.160 μg/mL) compared 
with that MCF-7 wildtype (2.017 μg/mL). 
286
Astuti I, et al., Resistance to doxorubicin...
FIGURE 3. A. Parental cell of MCF-7 wildtype (100x); B.MCF-7/Dox treatment 
periodically for 5 weeks. Arrow marker showed lamellipodia (100x)
A B
Expression of Pgp, caspase 3, estrogen 
receptor level
Immunohistochemistry assay was 
conducted to observe the Pgp, caspase 3, 
and estrogen receptor expressions levels. 
The labelled binding between antibody 
and antigen produced brown colour 
on the cytoplasm of the cells indicating 
that the cell was Pgp positive cell. The 
observation showed that the expression 
level of Pgp positive cell on MCF-7/Dox 
was higher than MCF-7 wild type. 
Caspase 3 expression observation 
using immunohistochemistry was done 
to characterize the MCF-7 cell line. The 
brown colour on the nucleus of the cell 
was the indicator of the expression of the 
ER. based on analysis of level expression 
of targets protein semi-quantitatively 
through image quantificationby using 
Image J software, by the total amount of 
27-29 cell field of view, the significance 
level expression of Pgp and ERof 9.191% 
and 9.557%, respectively  from a field of 
view, which can observe in FIGURE 4.
FIGURE 4. MCF-7 and MCF-7/Dox parental cell viability assay  using 
the gradual Dox concentration
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Unexpressed miR-145 on MCF-7 Cell 
line
qPCR was conducted to measure the 
expression of miR-145. The expression 
level of miR-145 was undetected. These 
results were confirmed by normal 
expression and observed in U6 snRNA 
as gene reference and UniSp6 as the 
normalization reference (FIGURE 5). 
This condition occurs in both cells, MCF-
7/Dox and wild-type MCF-7 which shown 
in FIGURE 6.
 
FIGURE 5. Histochemistry results on parental cell line, among others negative 
control (A), caspase 3 (B), expression ER in nucleus (C), and Pgp in MCF-
7 (D), expression of Pgp in cytoplasm and cell membrane of MCF-7/Dox 
(E), protein expression was detected with brown on  the sample showed 
by arrow (400x).
FIGURE 6. Quantification curve/ amplification curve on expression of miR-
451 byBiorad CFX ManagerTM software
A B
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The results showed of level 
expression of U6 snRNA with the length 
107 bp and Unisp6 have a length less of 100 
bp. Three-time replicates experiments 
resulted in the similar phenomenon 
unexpressed miR-451 on qPCR.
FIGURE 7. Confirmation of amplification of qRT PCR products through 
electrophoresis. The black arrow shows the ribbon of the U6 SnRNA 
product with a length of 107bp and the red arrow shows the ribbon of 
UniSp6 products with a length of <100bp
DISCUSSION
Prediction analysis of miR451 
toward mRNA MDR was a validation of 
prediction insilico analysis used hybrid 
RNA.  According to Brennek at al.14 the 
principle of complementation/base 
pairing and thermodynamic binding 
between miRNA and mRNA target. 
The binding position miR451 was on 
3’UTR sequence with 5 base nucleotide 
that complimented on 5’UTR position. 
Thermodynamically all interaction 
resulted from a value of minimum free 
energy of -6.10 kJ/mol. According to 
Leitner,15 the binding of miRNA and mRNA 
was inversely proportional to ∆G value. 
Based on principal thermodynamic by 
Gibbs there were chemical bonds, the 
value of ∆G negative resulted by insilico 
analysis showed spontaneity reaction 
between miR451 and MDR1.
The development prognosis 
biomarker research on the cell line of 
cancer resistance is the pharmacological 
and chemical drugs. The multilevel drugs 
treatment iso ne way that used to induce 
cell line toward cell cancer resistance.9 
Overexpression and unexpressed 
caspase 3 on cell line MCF-7 in accordance 
with previous studies. ER is a protein 
that playsroles in proliferation and 
metastasis signalling pathways whereas 
caspase 3 roles in apoptosis regulation. 
Adaptation of induction regulation 
by Doxaccordance with McCubrey et 
al.16 showed reactive oxygen species 
(ROS) accumulation that caused by 
Dox. This condition can increasing 
excessive phosphorylation Raf/MEK/ERK 
pathway that played important role as 
activation inducer of the transcription 
factor on Gene MDR1. Overexpression 
of Pgp on MCF-7/Dox  was found with 
significant value in cytoplasm and 
membrane cell. Mechanism expression 
of Pgp was adaptive mechanism cellular 
accumulated in the cytoplasm through 
efflux pump mechanism. The results 
of analysis assay IC50 on cell line MCF-7 
were overexpression more 7.5 fold times 
compared with cell line parental. It was 
resulted by physiological adaptation of 
increasing dose of Dox that previously 
administrated, which also affect the 
upregulation of Pgp expression level. 
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According to  Davis et al.17 there 
was resistance mechanism through 
increased expression of BCL-2, this might 
have been expected of Bcl-2 produced 
by Dox. Free radical is able to activate 
Raf/MEK/ERK signalling pathway via 
phosphorylation cascade. Protein Bcl-2 
is a protein that playsrole in apoptosis 
to increase proliferation and able to 
increase viability cell resistance. The 
morphologically on MCF-7/Doxisfound 
lamellopodia structure. The study 
result of Lukyanova et al.6 showed the 
activation of Rac-1 as extracellular 
response activated Pak1 so that induced 
phosphorylation myosin and F-actin on 
growing cytoskeleton and lamellopodia.
MiRNA is one type of non-coding 
RNA that expressed endogenously 
and plays role in regulating gene 
expression via post-transcriptional 
inhibition mechanisms. qPCR isone 
type of methods that used as detection 
methods to quantification miRNA.18 The 
results analysis of miR-451 expression 
was unexpressed while U6 snRNA 
expressed significantly. It was role as 
small nucleolar RNA housekeeping 
gene, which act as catalyst splicing on 
the mammalian cell.19,20 The Previous 
study performed inconsistent from 
several types of research about miRNA 
expression, it was suspected because 
of the change of physiology factor on 
cell line material. Previous observation 
has been conducte by Osborne et al.21 
on MCF-7cell line in several different 
laboratories. It was known to form 
the same morphology, but it occurred 
differences in growth rates, karyotypes, 
and activated significantly protein.21 It 
was expected to occur because the using 
of trypsin upon subculture to remove the 
adherent cell from substratum repeatedly 
on MCF-7 cell line which could led to 
conformational change of proteins in the 
cells via proteolytic activity.22 The others 
mechanism enabled to occur disruption 
expression on miR-451 because due the 
mutations on the gene encode miR451, 
but it is rare.23
Based on the results of research had 
been done, it suspected abnormalities 
on protein activated which played role 
in biogenesis mechanism of miRNA. 
Although visually, the parental MCF-7 
cell line used in this study possess similar 
morphological appearance compared 
to MCF-7 cell line, the alteration of 
gene expression or protein activity had 
possibly occurred in this cell line.
The changes of profile protein that 
contribute to miR451 biogenesis were 
one of the things that may be causing 
interference on the pri-miRNA into 
mature miRNA.24 Currently, the main 
protein was known as a regulator of 
miRNA biogenesis among others Drosha, 
Argonaute (Ago), Dicer, DGCR, TRBP, and 
RISC protein complex, while the protein 
which have role in this mechanism 
unclear. The changes on proteins that 
play role in biogenesis miRNA were 
presumed to disruption to cutting process 
pri-miRNA to mature miRNA, it resulted 
in changes in the sequence of bases, 
either point mutations or frameshift 
mutation on mature miRNA. In the 
laboratory, this study has been shown 
unexpressed of miR451 on MCF-7 cell 
line and MCF7/Dox because of changes 
characterization. It was confirmed 
through literary and in-silico analysis 
that performed expression and strong 
chemical bonds of miR451 and mRNA 
MDR1on MCF-7cell line. The research 
also had been shown increasingly level 
expression of Pgp independently on 
MCF-7/Dox which was not affected by 
expression of miR451.
CONCLUSIONS
The miR451 expression on both 
MCF-7 and MCF-7/Dox cell lines under 
go down regulation. On MCF-7/Dox cell 
line, the downregulation is associated 
withover expression of Pgpas indicated 
its higher expression compare to that 
on MCF-7 wild-type. It is concludet that 
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the Pgp over expression is associated 
with the MCF-7 cell line resistance to 
doxorubicin. 
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